Biota says to stop developing drug pending contract decision
April 29 (Reuters) - Biota Pharmaceuticals Inc said a U.S. agency has asked the company to stop developing its experimental influenza drug, pending a decision related to the company's contract with the agency.
The Biomedical Advanced Research and Development Authority (BARDA) had awarded a contract to the company in 2011 for the development of laninamivir octanoate as a potential treatment for influenza A and B infections. (Reporting by Shailesh Kuber; Editing by Saumyadeb Chakrabarty)
© Thomson Reuters 2017 All rights reserved.